The primary focus of EVF's scientific program is on facilitating translational research from discovery to early phase I/II clinical development.
Since its inception, EVF has successfully collaborated with different academic groups and supported the development of a number of HIV vaccine candidates from bench to clinic.
EVF has sponsored or co-sponsored multiple phase I/II HIV Vaccine Trials in Europe and Africa, in both prophylactic and therapeutic settings. These trials are funded and co-funded by European Commission 5th and 7th Framework Programs, Agence nationale de recherches sur le sida et les hépatites virales (ANRS) of Inserm, International HIV Vaccine Trial Network (IAVI), HIV Vaccine Trial Network (HVTN)/National Institute of Health (NIH) and European and Developing Countries Clinical Trials Partnership (EDCTP).
More recently, EVF is expanding its portfolio to other infectious disease areas through providing scientific project management support to large research consortia with the focus on facilitating the development from bench to clinic. To this end, EVF engages a pool of experts from manufacturing, to regulatory to clinical trials.